ES2723436T3 - Derivados de pirrolopirimidina como antagonistas del receptor NMDA NR2B - Google Patents
Derivados de pirrolopirimidina como antagonistas del receptor NMDA NR2B Download PDFInfo
- Publication number
- ES2723436T3 ES2723436T3 ES15779059T ES15779059T ES2723436T3 ES 2723436 T3 ES2723436 T3 ES 2723436T3 ES 15779059 T ES15779059 T ES 15779059T ES 15779059 T ES15779059 T ES 15779059T ES 2723436 T3 ES2723436 T3 ES 2723436T3
- Authority
- ES
- Spain
- Prior art keywords
- fluoro
- optionally substituted
- receptor antagonists
- alkyl
- nr2b receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050692P | 2014-09-15 | 2014-09-15 | |
| PCT/US2015/050267 WO2016044323A1 (en) | 2014-09-15 | 2015-09-15 | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2723436T3 true ES2723436T3 (es) | 2019-08-27 |
Family
ID=54293326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15779059T Active ES2723436T3 (es) | 2014-09-15 | 2015-09-15 | Derivados de pirrolopirimidina como antagonistas del receptor NMDA NR2B |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9567341B2 (enExample) |
| EP (1) | EP3194403B1 (enExample) |
| JP (1) | JP6612331B2 (enExample) |
| KR (1) | KR102569031B1 (enExample) |
| CN (1) | CN106715435B (enExample) |
| AU (1) | AU2015317886A1 (enExample) |
| CA (1) | CA2957898C (enExample) |
| DK (1) | DK3194403T3 (enExample) |
| ES (1) | ES2723436T3 (enExample) |
| IL (1) | IL251027A0 (enExample) |
| MX (1) | MX2017002775A (enExample) |
| RU (1) | RU2017107558A (enExample) |
| SG (1) | SG11201701853YA (enExample) |
| WO (1) | WO2016044323A1 (enExample) |
| ZA (1) | ZA201701069B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2950285A1 (en) | 2014-06-04 | 2015-12-10 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| ES2723436T3 (es) | 2014-09-15 | 2019-08-27 | Rugen Holdings Cayman Ltd | Derivados de pirrolopirimidina como antagonistas del receptor NMDA NR2B |
| EP3253761A4 (en) | 2015-02-04 | 2018-06-20 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists |
| EP3303323B1 (en) | 2015-06-01 | 2020-01-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| DK3720855T3 (da) * | 2017-12-08 | 2021-11-08 | Boehringer Ingelheim Int | Imidazopyridinderivater og avendelsen deraf som medikament |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| CN117185897A (zh) * | 2023-08-31 | 2023-12-08 | 上海泰坦科技股份有限公司 | 一种二氟甲基卤苯的合成方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9802862A3 (en) | 1995-08-11 | 1999-05-28 | Pfizer | (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate and pharmaceutical compositions containing it for treating cns disorders |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| CZ20032258A3 (cs) * | 2001-02-23 | 2004-01-14 | Merck & Co., Inc. | N-substituované nearylové heterocyklické sloučeniny |
| KR20060017839A (ko) | 2003-06-04 | 2006-02-27 | 머크 앤드 캄파니 인코포레이티드 | Ｎｍｄａ／ｎｒ2ｂ 길항제로서 3-플루오로-피페리딘 |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| WO2005019221A1 (en) * | 2003-08-15 | 2005-03-03 | Merck & Co., Inc. | 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| CA2575430A1 (en) | 2004-08-03 | 2006-02-16 | Merck & Co., Inc. | 1,3-disubstituted heteroaryl nmda/nr2b antagonists |
| WO2006069287A1 (en) | 2004-12-22 | 2006-06-29 | Merck & Co., Inc. | Process for making substituted piperidines |
| AU2006236625A1 (en) * | 2005-04-19 | 2006-10-26 | Merck & Co., Inc. | N-alkyl-azacycloalkyl NMDA/NR2B antagonists |
| DK1913000T3 (da) | 2005-07-29 | 2012-03-12 | Pfizer Prod Inc | Pyrrolo[2,3-D]pyrimidinderivater; deres mellemprodukter og syntese |
| WO2007061868A2 (en) | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| MX2009006517A (es) | 2006-12-27 | 2009-06-26 | Sanofi Aventis | Nuevos derivados de isoquinolina e isoquinolinona sustituidos. |
| WO2010015637A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| WO2011090666A2 (en) | 2009-12-28 | 2011-07-28 | Afraxis, Inc. | Methods for treating autism |
| AU2011239966B2 (en) | 2010-04-16 | 2014-05-08 | Ac Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| EP2580213A4 (en) | 2010-06-09 | 2013-12-25 | Afraxis Holdings Inc | 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
| WO2011159945A2 (en) | 2010-06-16 | 2011-12-22 | Afraxis, Inc. | Methods for treating neurological conditions |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| US9278910B2 (en) | 2011-05-31 | 2016-03-08 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
| CN104321057B (zh) | 2012-04-20 | 2016-09-14 | Ucb医药有限公司 | 用于治疗帕金森病的方法 |
| KR20150110784A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| CA2947976A1 (en) | 2014-05-06 | 2015-11-12 | Northwestern University | Combinations of nmdar modulating compounds |
| CA2950285A1 (en) | 2014-06-04 | 2015-12-10 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| ES2723436T3 (es) | 2014-09-15 | 2019-08-27 | Rugen Holdings Cayman Ltd | Derivados de pirrolopirimidina como antagonistas del receptor NMDA NR2B |
| US20180271869A1 (en) | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016100349A2 (en) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| EP3253761A4 (en) | 2015-02-04 | 2018-06-20 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists |
| EP3303323B1 (en) | 2015-06-01 | 2020-01-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
-
2015
- 2015-09-15 ES ES15779059T patent/ES2723436T3/es active Active
- 2015-09-15 DK DK15779059.3T patent/DK3194403T3/en active
- 2015-09-15 WO PCT/US2015/050267 patent/WO2016044323A1/en not_active Ceased
- 2015-09-15 JP JP2017514306A patent/JP6612331B2/ja active Active
- 2015-09-15 KR KR1020177010056A patent/KR102569031B1/ko active Active
- 2015-09-15 AU AU2015317886A patent/AU2015317886A1/en not_active Abandoned
- 2015-09-15 US US14/855,010 patent/US9567341B2/en active Active
- 2015-09-15 EP EP15779059.3A patent/EP3194403B1/en active Active
- 2015-09-15 SG SG11201701853YA patent/SG11201701853YA/en unknown
- 2015-09-15 RU RU2017107558A patent/RU2017107558A/ru not_active Application Discontinuation
- 2015-09-15 CN CN201580049617.5A patent/CN106715435B/zh active Active
- 2015-09-15 CA CA2957898A patent/CA2957898C/en active Active
- 2015-09-15 MX MX2017002775A patent/MX2017002775A/es unknown
-
2017
- 2017-02-09 US US15/428,321 patent/US9968610B2/en active Active
- 2017-02-13 ZA ZA2017/01069A patent/ZA201701069B/en unknown
- 2017-03-08 IL IL251027A patent/IL251027A0/en unknown
-
2018
- 2018-04-24 US US15/961,553 patent/US10420768B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2957898A1 (en) | 2016-03-24 |
| DK3194403T3 (en) | 2019-04-15 |
| KR20170049602A (ko) | 2017-05-10 |
| US10420768B2 (en) | 2019-09-24 |
| JP6612331B2 (ja) | 2019-11-27 |
| US20170209449A1 (en) | 2017-07-27 |
| JP2017526724A (ja) | 2017-09-14 |
| CN106715435A (zh) | 2017-05-24 |
| SG11201701853YA (en) | 2017-04-27 |
| EP3194403A1 (en) | 2017-07-26 |
| IL251027A0 (en) | 2017-04-30 |
| WO2016044323A1 (en) | 2016-03-24 |
| EP3194403B1 (en) | 2019-02-06 |
| ZA201701069B (en) | 2019-07-31 |
| BR112017004868A2 (pt) | 2017-12-12 |
| CN106715435B (zh) | 2019-10-01 |
| RU2017107558A (ru) | 2018-10-18 |
| US9968610B2 (en) | 2018-05-15 |
| US20160075713A1 (en) | 2016-03-17 |
| US9567341B2 (en) | 2017-02-14 |
| KR102569031B1 (ko) | 2023-08-22 |
| US20180303834A1 (en) | 2018-10-25 |
| RU2017107558A3 (enExample) | 2019-03-18 |
| AU2015317886A1 (en) | 2017-03-09 |
| CA2957898C (en) | 2023-02-21 |
| MX2017002775A (es) | 2017-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2723436T3 (es) | Derivados de pirrolopirimidina como antagonistas del receptor NMDA NR2B | |
| CY1123443T1 (el) | Οξεα καρβαμοϋλοξυμεθυλ-τριαζολ-κυκλοεξυλιου ως ανταγωνιστες lpa | |
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| CY1125110T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| UY35975A (es) | Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia | |
| MX379579B (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso. | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| PE20151606A1 (es) | DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| CR20140089A (es) | Nuevos derivados bicíclicos de dihidroquinolina-2-ona | |
| UY35991A (es) | Bencimidazol-2-aminas como inhibidores de midh1 | |
| EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| UY36003A (es) | Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina. | |
| MX2017001554A (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias. | |
| CY1118541T1 (el) | D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης | |
| CO2017005498A2 (es) | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia | |
| UY35708A (es) | Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico | |
| CU20160148A7 (es) | Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2 |